EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness of a drug called erlotinib in treating
the tumor. This is a multi-center pilot study that explores efficacy and molecular effects of
high dose weekly erlotinib for recurrent EGFR vIII mutant malignant gliomas, and correlate
molecular profile of pre-treatment tissue with outcome.